The Buck Institute Board of Trustees has three new members as of Dec. 7.
Edward O. Lanphier III, the founder of Sangamo BioSciences, Inc.; Nathaniel “Ned” Eames David, PhD, an entrepreneur who has co-founded several technology companies; and Richard “Dick” Bodman, the managing partner for VMS Fund Administration, have joined the board.
Lanphier, who lives in Marin County, has over 25 years of experience in the pharmaceutical and biotechnology industry. He has served as president, CEO and a board member of Sangamo since its inception in 1995. Lanphier has held various positions at Somatix Therapy Corporation, BioGrowth, Inc., Biotherapeutics, Inc., and Synergen Inc. Lanphier, who currently serves on the board of the Biotechnology Institute, got his start in the industry at Eli Lilly and Company in the strategic business planning biotechnology group. He holds a BA in Biochemistry from Knox College.
Over the last 13 years, David has co-founded five technology companies (Syrrx, Achaogen, Kythera Biopharmaceuticals, Sapphire Energy and Kilimanjaro Energy) that have collectively raised more than $800 million in financing and currently have more than 350 employees. David, who lives in Marin, was named one of the Innovators Under 35 by the MIT Technology Review in 2002. He holds numerous pending and issued patents in fields such as nanovolume crystallography, antibiotic resistance, and aesthetic medicine. He earned a PhD from the University of California, Berkeley, in Molecular and Cellular Biology.
Bodman lives in Naples, Florida, and holds a BS in Engineering from Princeton University and an MS in Industrial Management from the Massachusetts Institute of Technology. In addition to being a managing partner for VMS Fund Administration, which offers turn-key administrative services to private equity funds, he is also managing general partner for AT&T Ventures, the private equity wing of AT&T. He has also served as president of the Washington National Investment Corporation, president and CEO of COMSAT General Corporation, a manager at DuPont, an assistant director of the Office of Management and Budget, and an assistant secretary to the Department of the Interior. He is currently a director of Deloitte LLP, a DC-based venture capital fund, and the chair of the board of Purthread Technologies.
“I am extremely excited to welcome these new board members,” said Brian Kennedy, PhD, President and CEO of the Buck Institute. “Their expertise is just what we need as we strive to translate our discoveries about aging and age-related diseases into real-world solutions for aging populations around the globe.” Noting that all of the three board members are extremely active in their various fields, Kennedy added, “I think their willingness to devote time and energy to the Buck Institute is a testament to our success and to our commitment to extend the healthy years of human life.”
About the Buck Institute for Research on Aging
The Buck Institute is the U.S.’s first and foremost independent research organization devoted to Geroscience – focused on the connection between normal aging and chronic disease. Based in Novato, California, the Buck is dedicated to extending “healthspan,” the healthy years of human life and does so utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and those focused on specific diseases. Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer’s, Parkinson’s, cancer, cardiovascular disease, osteoporosis, macular degeneration, diabetes and stroke. In their collaborative research, they are supported by the most recent developments in genomics, proteomics and bioinformatics. For more information: www.thebuck.org.